aromatase inhibitor
Showing 1 - 25 of 7,800
Compare Overall Survival in Medicare Metastatic Breast Cancer
Active, not recruiting
- Breast Cancer
- Palbociclib
- Aromatase Inhibitor
-
New York, New YorkPfizer New York
Oct 11, 2023
Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)
Active, not recruiting
- Breast Cancer
- Capecitabine
- Aromatase Inhibitor
-
Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain Trial in Los Angeles, Torrance (Tart
Not yet recruiting
- Breast Cancer
- +2 more
- Tart Cherry
- Omega 3 FA (Fish Oil)
-
Los Angeles, California
- +1 more
Nov 7, 2023
Blood Vessel Function in Postmenopausal Women With Breast Cancer
Active, not recruiting
- Breast Cancer
- anastrozole
- +3 more
-
Rochester, MinnesotaMayo Clinic
Jan 17, 2023
Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), Breast Cancer Trial in Tucson (Initial blood draw, Initial SWE
Completed
- Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS)
- Breast Cancer
- Initial blood draw
- +4 more
-
Tucson, ArizonaUniversity of Arizona Cancer Center
Dec 16, 2022
Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian
Not yet recruiting
- Hormone-receptor-positive Breast Cancer
- +3 more
- Aromatase inhibitor
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Apr 5, 2023
Vasomotor Symptoms Trial (oxybutynin ER, Paroxetine CR)
Not yet recruiting
- Vasomotor Symptoms
- oxybutynin ER
- Paroxetine CR
- (no location specified)
Dec 1, 2022
Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
Recruiting
- Anatomic Stage 0 Breast Cancer AJCC v8
- +4 more
- Non-Interventional Study
-
Jacksonville, FloridaMayo Clinic in Florida
Oct 24, 2023
Musculoskeletal Syndrome Trial in Minneapolis (CBD-dominant, THC dominant)
Recruiting
- Musculoskeletal Syndrome
- CBD-dominant
- THC dominant
-
Minneapolis, MinnesotaUniversity of Minnesota
Jun 28, 2023
Palbociclib in Combination With an Aromatase Inhibitor
Recruiting
- Metastatic Breast Cancer
- Palbociclib + an aromatase inhibitor
- Aromatase inhibitor
-
New York, New York10017
May 2, 2022
Breast Cancer, ER Positive Breast Cancer Trial in Lebanon (Letrozole 2.5mg)
Recruiting
- Breast Cancer
- ER Positive Breast Cancer
- Letrozole 2.5mg
-
Lebanon, New Hampshire
- +1 more
Dec 19, 2022
Metastatic Breast Cancer Trial in Springfield, Rochester, Lebanon (17B-estradiol, Letrozole, Anastrozole)
Active, not recruiting
- Metastatic Breast Cancer
- 17B-estradiol
- +3 more
-
Springfield, Massachusetts
- +2 more
Nov 1, 2022
Arthralgia, Breast Cancer Trial in Ann Arbor (Cannabidiol (CBD))
Recruiting
- Arthralgia
- Breast Cancer
- Cannabidiol (CBD)
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Sep 21, 2022
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial
Recruiting
- Anatomic Stage I Breast Cancer AJCC v8
- +2 more
- Questionnaire Administration
- Tonation Breathing Technique
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Musculoskeletal Pain Trial in Frederiksberg (Physiotherapeutic treatment and medical care, medical care)
Recruiting
- Musculoskeletal Pain
- Physiotherapeutic treatment and medical care
- medical care
-
Frederiksberg, DenmarkParker Instituttet, Frederiksberg Hospital
Oct 7, 2022
Pre-menopausal Metastatic Breast Cancer Patients Treated With
Completed
- Metastatic Breast Cancer
- Palbociclib + aromatase inhibitor
- Aromatase inhibitor
-
New York, New YorkPfizer New York
Feb 25, 2022
Examining the Effect of Endocrine Therapy on Aging
Recruiting
- Breast Neoplasm Female
- +2 more
- Aromatase inhibitor
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Jan 17, 2023
Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)
Not yet recruiting
- Breast Cancer
- M1774
- Fulvestrant injection
-
Marseille, FranceInstitut Paoli Calmettes
Aug 9, 2023
Breast Cancer, Hormone Receptor Positive Tumor Trial in Tampa (Durvalumab, Anastrozole 1mg, Letrozole 2.5mg)
Terminated
- Breast Cancer
- Hormone Receptor Positive Tumor
- Durvalumab
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
May 27, 2022
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer Trial in
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +9 more
- anastrozole
- +3 more
-
Boston, Massachusetts
- +1 more
Sep 9, 2022
Arthralgia Trial (acupuncture, Guizhi-Shaoyao-Zhimu decoction)
Not yet recruiting
- Arthralgia
- acupuncture
- Guizhi-Shaoyao-Zhimu decoction
- (no location specified)
Mar 2, 2022